Vincent Rajkumar, MD
vincentrk.bsky.social
Vincent Rajkumar, MD
@vincentrk.bsky.social
Editor in Chief, Blood Cancer Journal; Professor, Mayo Clinic; Associate Editor, Mayo Clinic Proceedings; Oncologist, Cancer Research, Myeloma.
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM

5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. www.nejm.org/doi/abs/10.1...
October 18, 2025 at 12:57 PM
9. All the active drugs for myeloma in one simple table. Black font = approved drugs; blue font = investigational.
December 8, 2024 at 3:56 PM
5. True Penta-Refractory myeloma (refractory to PI, Imid, CD38, alkylator, and BCMA targeted approach).
msmart.org #ASH24
December 8, 2024 at 3:56 PM
4. Second or later relapse
mSMART.org #ASH24
December 8, 2024 at 3:56 PM
3) First Relapse

I don’t recommend CART in first relapse even though it’s approved except in very selected patients (eg., high risk progressing early while on quad).

msmart.org #ASH24
December 8, 2024 at 3:56 PM
2. Newly diagnosed transplant eligible. Quadruplet induction.

See below for transplant timing and maintenance. #ASH24
December 8, 2024 at 3:56 PM
My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24
#ASH24VR

1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.
December 8, 2024 at 3:56 PM